Physician profile
Peter R Graze
NPI 1669400784
$7,983.60
in general payments reported to CMS, 2019-2025
64 companies · $1,236 in 2025
The $1,236 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,022 · 2020: $2,202 · 2021: $112 · 2022: $816 · 2023: $189 · 2024: $1,407 · 2025: $1,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,831.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $1,954.68 | 2019-2025 | Reblozyl, Opdualag |
| Abbvie INC. | $790.46 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $563.06 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $483.30 | 2019-2025 | Enhertu, Lynparza |
| Amgen INC. | $342.69 | 2019-2025 | Evenity, Kyprolis, Blincyto |
| Pfizer INC. | $317.90 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $238.82 | 2019-2024 | Opdivo |
| Merck Sharp & Dohme LLC | $215.99 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Incyte Corporation | $210.97 | 2019-2025 | Monjuvi, Zynyz, Pemazyre |
| Janssen Biotech, INC. | $185.98 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| Genentech USA, INC. | $171.77 | 2019-2025 | Itovebi, Venclexta, Gazyva |
| Servier Pharmaceuticals LLC | $156.76 | 2024 | |
| Daiichi Sankyo INC. | $152.86 | 2019-2025 | Enhertu, Injectafer |
| Genzyme Corporation | $147.67 | 2019-2025 | |
| Glaxosmithkline, LLC. | $99.57 | 2020-2025 | Jemperli, Zejula, Blenrep |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Graze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.